While this data are promising, future testing in additional GBM models, including syngeneic models using immunocompetent mice, models that may exhibit varying levels of sensitivity to TRAIL, and models that replicate the heterogeneous nature of GBM, should be explored to gain a more complete understanding of the influence of CLIP scaffolds on the efficacy of cell therapies against GBM. Here, TNFSF10 is linked to glioblastoma.